Federal Register / Vol. 72, No. 100 / Thursday, May 24, 2007 / Notices 29137 

Dated: May 18, 2007. 

Susan K. Fawcett, 

Records Officer, U.S. Patent and Trademark 

Office, Office of the Chief Information Officer, 

Customer Information Services Group, Public 

Information Services Division. 

[FR Doc. E7–10042 Filed 5–23–07; 8:45 am] 

BILLING CODE 3510–16–P 

DEPARTMENT OF COMMERCE 

Patent and Trademark Office 

[Docket No. PTO–P–2007–0021] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 4,927,855; 

NUVIGIL(TM) (armodafinil) 

AGENCY: United States Patent and 

Trademark Office, Commerce. 

ACTION: Notice of interim patent term 

extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued an order 

granting interim extension under 35 

U.S.C. 156(d)(5) for a one-year interim 

extension of the term of U.S. Patent No. 

4,927,855. 

FOR FURTHER INFORMATION CONTACT: 

Mary C. Till by telephone at (571) 272–

7755; by mail marked to her attention 

and addressed to the Commissioner for 

Patents, Mail Stop Hatch-Waxman PTE., 

P.O. Box 1450, Alexandria, VA 22313–

1450; by fax marked to her attention at 

(571) 273–7755, or by e-mail to 

Mary.Till@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to a year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On May 7, 2007, Cephalon, Inc., an 

agent of Laboratoire L. Lafon, the owner 

of record in the United States Patent and 

Trademark Office of U.S. Patent No. 

4,927,855, timely filed an application 

under 35 U.S.C. 156(d)(5) for an interim 

extension of the term of U.S. Patent No. 

4,927,855. The patent claims the human 

drug product NUVIGIL(TM) (armodafinil) 

and a method of said product. The 

application indicates, and the Food and 

Drug Administration has confirmed, 

that a new drug application (NDA 21–

875) for the human drug product 

NUVIGIL(TM) (armodafinil) has been 

filed and is currently undergoing 

regulatory review before the Food and 

Drug Administration for permission to 

market or use the product commercially. 

Review of the application indicates 

that, except for permission to market or 

use the product commercially, the 

subject patent would be eligible for an 

extension of the patent term under 35 

U.S.C. 156, and that the patent should 

be extended for one year as required by 

35 U.S.C. 156(d)(5)(B). Because it is 

apparent that the regulatory review 

period will continue beyond the original 

expiration date of the patent (May 22, 

2007), interim extension of the patent 

term under 35 U.S.C. 156(d)(5) is 

appropriate. 

An interim extension under 35 U.S.C. 

156(d)(5) of the term of U.S. Patent No. 

4,927,855 is granted for a period of one 

year from the expiration date of the 

patent, i.e., until May 22, 2008. 

Dated: May 18, 2007. 

Jon W. Dudas, 

Under Secretary of Commerce for Intellectual 

Property and Director of the United States 

Patent and Trademark Office. 

[FR Doc. E7–10084 Filed 5–23–07; 8:45 am] 

BILLING CODE 3510–16–P 

DEPARTMENT OF DEFENSE 

Office of the Secretary 

Sub Committee Meeting of the 

President’s Commission on Care for 

America’s Returning Wounded 

Warriors 

AGENCY: Department of Defense. 

ACTION: Federal Advisory Committee 

Sub Committee Meeting Notice. 

SUMMARY: Pursuant to the Federal 

Advisory Committee Act of 1972 (5 

U.S.C., Appendix, as amended), the 

Sunshine in the Government Act of 

1976 (5 U.S.C. 552b, as amended) and 

41 Code of Federal Regulations (CFR) 

102–3.140 thorough 160, the 

Department of Defense announces the 

forthcoming sub committee meeting: 

Subcommittees of the Commission 

will conduct preparatory work meetings 

at Ft. Bragg and Camp Lejeune, North 

Caroline June 19th to gather 

information, conduct research and 

analyze relevant issues and facts in 

preparation for a meeting of the 

Commission. Pursuant to section 102–

3.160(a) of 41 Code of Federal 

Regulations (CFR), these subcommittee 

meetings are not open to the public, and 

the subcommittees are required to report 

their findings to the Commission for 

further deliberation. 

Dated: May 18, 2007. 

L.M. Bynum, 

Alternate OSD Federal Register Liaison 

Officer, DoD. 

[FR Doc. 07–2596 Filed 5–22–07; 10:59 am] 

BILLING CODE 5001–06–M 

DEPARTMENT OF DEFENSE 

Office of the Secretary 

Sub Committee Meeting of the 

President’s Commission on Care for 

America’s Returning Wounded 

Warriors 

AGENCY: Department of Defense. 

ACTION: Federal Advisory Committee 

Sub Committee Meeting Notice. 

SUMMARY: Pursuant to the Federal 

Advisory Committee Act of 1972 (5 

U.S.C., Appendix, as amended), the 

Sunshine in the Government Act of 

1976 (5 U.S.C. 552b, as amended) and 

41 Code of Federal Regulations (CFR) 

102–3.140 through 160, the Department 

of Defense announces the forthcoming 

sub committee meeting: 

Subcommittees of the Commission 

will conduct preparatory work meetings 

in the New Jersey area June 15th to 

gather information, conduct research 

and analyze relevant issues and facts in 

preparation for a meeting of the 

Commission. Pursuant to section 102–

3.160(a) of 41 Code of Federal 

Regulations (CFR), these subcommittee 

meetings are not open to the public, and 

the subcommittees are required to report 

their findings to the Commission for 

further deliberation. Locations include 

the East Orange VA Health Center. 

Additionally, the Sub Committees may 

visit public and private hospitals in the 

area for investigation of Centers of 

Excellence that apply to the 

Commission’s Charter. 

Dated: May 18, 2007. 

L.M. Bynum, 

Alternate OSD Federal Register Liaison 

Officer, DoD. 

[FR Doc. 07–2597 Filed 5–22–07; 8:45 am] 

BILLING CODE 5001–06–M 

ELECTION ASSISTANCE COMMISSION 

Sunshine Act Notice 

AGENCY: United States Election 

Assistance Commission. 

ACTION: Notice of Public Teleconference 

Meetings for the Working 

Subcommittees of the Technical 

Guidelines Development Committee. 

DATES AND TIMES: 


rmajette on PROD1PC67 with NOTICES